Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Summary

The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery

Timeline

Start

2006-08

Primary completion

2008-06

Completion

2008-06

Publications

• Gozes I, Blatt J, Guz LS. Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG). Transl Psychiatry. 2025 Oct 31;15(1):454. doi: 10.1038/s41398-025-03675-y.

Drugs

Indications